In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $52.06, marking a +2.1% move from the previous day. This change outpaced the S&P 500's 0.49% loss on the day. Elsewhere, the Dow ...

CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its ...

Intellia Therapeutics, a leading biotechnology company, announced that its CRISPR-based treatment for a rare swelling ...

The cultivar is giving the industry renewed confidence in the future, said Florida Citrus Mutual Board President Kevin ...

Recent studies highlight how artificial intelligence and CRISPR-based molecular tools are reshaping gastrointestinal diagnostics, from intestinal tuberculosis to colon polyp detection. AI-assisted ...

CRISPR gene editing specialist Intellia Therapeutics has announced positive topline results from the global Phase III HAELO ...

Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the ...

A new study by researchers at the Icahn School of Medicine at Mount Sinai overturns a longstanding assumption about how mRNA ...

Intellia’s in vivo CRISPR gene therapy for hereditary angioedema cut attack rates by 87% in a Phase III trial, prompting a rolling FDA submission. Novartis secured EU approval for the first oral ...

Addgene, a purpose-driven organization that joins with scientists around the world to reduce barriers to research and foster innovation, today announced that its strategic growth and expanded services ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) fell 7.6% Tuesday after the company announced the pricing of a public offering of common stock at a discount to its closing price. The biopharmaceutical ...